Internal Medicine, Hematology & Oncology · Cleveland, OH
NPI
1922254937
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
9500 Euclid Ave R35
Cleveland, OH, 44195
Phone (216) 445-9840
Groups this clinician bills Medicare through
Medicare paid, 2024
$30K
415 services
Medicare patients, 2024
136
Average age 72
Drug cost, 2024
$10.6M
722 prescriptions
Company payments, 2025
$11K
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Aaron T Gerds was code 99233 (hospital e&m - subsequent), 172 times for 43 patients. In total Aaron T Gerds billed 415 services in 13 codes, and Medicare paid $30K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-12-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 172 | 43 | $89.62 | $15K |
| 99215 Office E&M - Established | Facility | 76 | 53 | $96.05 | $7,300 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 66 | 53 | $12.47 | $823 |
| 99238 Hospital Discharge Management | Facility | 23 | 20 | $61.04 | $1,404 |
| 99214 Office E&M - Established | Office | 16 | 12 | $90.31 | $1,445 |
| 99214 Office E&M - Established | Facility | 14 | 14 | $57.67 | $807 |
By year: 2022 $30K for 354 services; 2023 $23K for 267 services; 2024 $30K for 415 services.
Medicare prescription drug claims, 2024
In 2024, the drug Aaron T Gerds prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 272 prescriptions and refills. In total Aaron T Gerds wrote 722 Medicare prescriptions that cost $10.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 272 | 272 | 37 | $4.8M |
| Ojjaara Momelotinib Dihydrochloride | 154 | 154 | 23 | $4.2M |
| Hydroxyurea Generic | 109 | 260 | 35 | $4,155 |
| Acyclovir Generic | 27 | 47 | Under 11 | $682 |
| Besremi Ropeginterferon Alfa-2b-Njft | 25 | 25 | Under 11 | $374K |
| Ayvakit Avapritinib | 23 | 23 | Under 11 | $839K |
| Vonjo Pacritinib Citrate | 13 | 13 | Under 11 | $326K |
| Pegasys Peginterferon Alfa-2a | 13 | 13 | Under 11 | $16K |
| Danazol Generic | 12 | 12 | Under 11 | $4,291 |
Brand drugs: 513 claims; generic drugs: 209 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Aaron T Gerds $11K ($8,916 in general payments such as food, travel and fees and $2,018 for research) from 8 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $6,053.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.